Navigation Links
MAP Pharmaceuticals to Present at Upcoming Investor Conferences
Date:8/9/2012

MOUNTAIN VIEW, Calif., Aug. 9, 2012 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will present at the following investor conferences:

Canaccord Genuity 32nd Annual Growth Conference
Thursday, August 16, at 11:30 a.m. ET in Boston

Stifel Nicolaus Annual Healthcare Conference
Thursday, September 6, at 8:00 a.m. ET in Boston

A live webcast of each presentation will be available on the Investor Relations section of MAP Pharmaceuticals' website at http://www.mappharma.com. A replay also will be available within 24 hours for seven days following each presentation.

About MAP Pharmaceuticals

MAP Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing new therapies to address undermet patient needs in neurology. The Company is developing LEVADEX®, an orally inhaled investigational drug for the acute treatment of migraine. The U.S. Food and Drug Administration (FDA) reviewed the New Drug Application (NDA) for LEVADEX and on March 26, 2012, the Company received a Complete Response letter with respect to this NDA. The Company completed an End-of-Review meeting with the FDA and plans to resubmit in the late third quarter/early fourth quarter 2012 timeframe. MAP Pharmaceuticals has entered into a collaboration agreement with Allergan, Inc. to co-promote LEVADEX to neurologists and pain specialists in the U.S. and Canada. The Company also applies its proprietary drug particle and inhalation technologies to generate new pipeline opportunities by enhancing the therapeutic benefits of proven drugs, while minimizing risk by capitalizing on their known safety, efficacy and commercialization history. Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.

CONTACT:
Lisa Borland
MAP Pharmaceuticals, Inc.
650-386-3122
lborland@mappharma.com


'/>"/>
SOURCE MAP Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Avanir Pharmaceuticals Reports Fiscal 2012 Third Quarter Financial And Business Results
2. Savient Pharmaceuticals Reports Second Quarter 2012 Financial Results
3. Auxilium Pharmaceuticals, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference
4. UCF nanoparticle discovery opens door for pharmaceuticals
5. Cadence Pharmaceuticals Reports Second Quarter 2012 Financial Results
6. Inspiration Biopharmaceuticals Expands Industry Expertise with Five New Executive Hires
7. Optimer Pharmaceuticals Reports Second Quarter 2012 Financial Results
8. MAP Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
9. Global Biopharmaceuticals Market 2011-2015
10. Patient Advocate Foundation and Jazz Pharmaceuticals Announce Partnership for Narcolepsy CareLine
11. Convergence Pharmaceuticals Announces Successful Completion of Phase I for CNV2197944 and Plans Phase II Studies in Neuropathic Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... 29, 2017  Applied BioMath ( www.appliedbiomath.com ... to drug research and development, today announced ... Inc. for quantitative systems pharmacology (QSP) support ... the treatment of cancer. ... GLP toxicology studies and first-in-human dose predictions ...
(Date:3/29/2017)... ... March 29, 2017 , ... ACEA Biosciences, ... disperses a quarterly travel award to noteworthy scientists who will be presenting research ... its new round of awards are being given to two postdoctoral fellows studying ...
(Date:3/29/2017)... 29, 2017 Research and Markets has announced ... Trends - Industry Forecast to 2025" report to their offering. ... The Global ... around 7.8% over the next decade to reach approximately $825.4 million ... estimates and forecasts for all the given segments on global as ...
(Date:3/29/2017)... , March 29, 2017 /PRNewswire/ -  GeneNews Limited ... BreastSentry™ , a new risk stratification test for breast ... lab, Innovative Diagnostics Laboratory ("IDL"). BreastSentry incorporates a blood-based biomarker ... and lifetime risk for developing breast cancer.   ... BreastSentry measures the ...
Breaking Biology Technology:
(Date:2/16/2017)... 2017  Genos, a community for personal genetic ... received Laboratory Accreditation from the College of American ... laboratories that meet stringent requirements around quality, accuracy ... "Genos is committed to maintaining the ... honored to be receiving CAP accreditation," said ...
(Date:2/13/2017)... SAN FRANCISCO , Feb. 13, 2017 /PRNewswire/ ... a centralized platform that is designed to enhance ... the latest release in the RSA Fraud & ... to enable organizations to leverage additional insights from ... anti-fraud tools to better protect their customers from ...
(Date:2/10/2017)... Research and Markets has announced the addition of ... Commercial Aspects" to their offering. ... Biomarkers play an important ... selection of treatment as well for monitoring the results. There ... modern medicine. Biochip/microarray technologies and next generation sequencing are also ...
Breaking Biology News(10 mins):